Last Updated : March 9, 2020
Details
Generic Name:
Olaparib
Project Status:
Not filed
Manufacturer:
AstraZeneca Canada
Brand Name:
Lynparza
Project Line:
Reimbursement Review
Project Number:
N/A
Tumour Type:
Breast
Indications:
Treatment of adult patients with deleterious or suspected deleterious germline BRCAmutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.
Review Status:
Not Filed
Recommendation Type:
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
Clarification:
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer.
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : March 9, 2020